| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
53,697 |
46,502 |
$3.41M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,966 |
9,492 |
$1.07M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
26,690 |
24,352 |
$1.01M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
7,787 |
7,114 |
$855K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
7,902 |
7,177 |
$819K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,475 |
4,162 |
$484K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,783 |
1,672 |
$208K |
| 87428 |
|
4,936 |
4,267 |
$135K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
10,190 |
8,878 |
$95K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,786 |
3,533 |
$90K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,264 |
2,881 |
$62K |
| 92587 |
|
1,566 |
1,421 |
$47K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,040 |
954 |
$32K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,085 |
956 |
$28K |
| 96127 |
|
1,469 |
1,261 |
$25K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
417 |
353 |
$25K |
| 99177 |
|
1,180 |
1,072 |
$21K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
987 |
858 |
$18K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
461 |
375 |
$14K |
| 99051 |
|
1,755 |
1,594 |
$12K |
| 83655 |
|
1,113 |
982 |
$11K |
| 36416 |
|
3,382 |
2,949 |
$10K |
| 99188 |
|
362 |
328 |
$7K |
| 94760 |
|
3,264 |
2,721 |
$4K |
| 99173 |
|
346 |
298 |
$2K |
| 87807 |
|
55 |
54 |
$536.12 |
| 96161 |
|
27 |
25 |
$468.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
29 |
27 |
$369.63 |
| 85018 |
|
4,034 |
3,597 |
$229.35 |
| 90686 |
|
9,687 |
9,010 |
$60.10 |
| 88738 |
|
1,554 |
1,450 |
$47.90 |
| 90677 |
|
1,343 |
1,082 |
$4.91 |
| 81002 |
|
172 |
168 |
$2.44 |
| 81003 |
|
1,700 |
1,598 |
$2.14 |
| 90670 |
|
4,151 |
3,918 |
$0.04 |
| 90685 |
|
60 |
57 |
$0.01 |
| 90707 |
|
553 |
536 |
$0.00 |
| 90380 |
|
31 |
31 |
$0.00 |
| 90681 |
|
1,028 |
938 |
$0.00 |
| 90633 |
|
1,188 |
1,042 |
$0.00 |
| 99072 |
|
710 |
646 |
$0.00 |
| 90734 |
|
71 |
68 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
18 |
18 |
$0.00 |
| 90716 |
|
578 |
557 |
$0.00 |
| 90744 |
|
883 |
824 |
$0.00 |
| 90698 |
|
4,783 |
4,382 |
$0.00 |
| 90656 |
|
1,221 |
1,085 |
$0.00 |
| 90697 |
|
246 |
206 |
$0.00 |
| 90619 |
|
35 |
35 |
$0.00 |
| 90651 |
|
52 |
49 |
$0.00 |
| 90696 |
|
15 |
14 |
$0.00 |